- by Health CanadaDocuments to announce multiple updates to the Prescription Drug List.
- by Health CanadaDocuments to announce multiple updates to the Prescription Drug List.
- by Health CanadaHealth Canada is seeking input from health care, industry, and other stakeholders about improving access to drugs and other health products for people in Canada to enhance the collective response to drug and other health product shortages. We are seeking your feedback on four key areas for action related to preventing shortages and better mitigating their impacts.
- by Health CanadaDocuments to announce the revision of the moxidectin veterinary listing on the Prescription Drug List.
- by Health CanadaDocuments to announce multiple updates to the Prescription Drug List.
- by Health CanadaThe consultation period for the proposed Agile Regulations and Guidance for the Licensing of Drugs and Medical Devices has been extended by an additional 30 days. This consultation will now close to new input on April 26, 2023, at 11:59pm Eastern Standard Time (EST).
- by Health CanadaThe purpose of this Notice of Amendment is to announce that Health Canada has removed “Betaine or its salts” from the Veterinary part of the Prescription Drug List (PDL). Only the Veterinary part of the PDL has been be revised.
- by Health CanadaDocuments to announce multiple updates to the Prescription Drug List.
- by Health CanadaHealth Canada has updated our Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19.
- by Health CanadaHealth Canada is proposing new targeted provisions and regulatory amendments to the Food and Drug Regulations and Medical Devices Regulations. These changes will continue to advance our modernization agenda and help to reduce regulatory irritants and roadblocks to innovation. We are seeking feedback on both the proposed regulations and on multiple guidance documents related to the proposal.
- by Health CanadaOn October 18, 2022, Health Canada authorized the expanded use of Evusheld as a treatment for adults and adolescents over 12 with mild to moderate COVID-19 symptoms.
- by Health CanadaOn October 13, 2022, Health Canada authorized the use of Actemra as a treatment for adults with severe COVID-19 who are in hospital.
- by Health CanadaDocuments to announce multiple updates to the Prescription Drug List.
- by Health CanadaDocuments to announce the Notice of Amendment to add metamizole (dipyrone) to the PDL.
- by Health CanadaNotice of Intent to Amend the Prescription Drug List (PDL) for Betaine.